On this page
Acetic Acid
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 018523-001 | ACETIC ACID 0.25% IN PLASTIC CONTAINER | SOLUTION | ACETIC ACID, GLACIAL | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 22 | Manufacturing (CMC) | Approved | September 26, 2014 | Standard |
| Supplement | 20 | Manufacturing (CMC) | Approved | September 28, 2011 | — |
| Supplement | 15 | Labeling | Approved | May 26, 1999 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | September 30, 1994 | Standard |
| Supplement | 13 | Manufacturing (CMC) | Approved | September 14, 1993 | Standard |
| Supplement | 10 | Manufacturing (CMC) | Approved | November 14, 1991 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | March 26, 1991 | Standard |
| Supplement | 9 | Manufacturing (CMC) | Approved | May 18, 1990 | Standard |
| Supplement | 8 | Manufacturing (CMC) | Approved | July 26, 1989 | Standard |
| Supplement | 7 | Manufacturing (CMC) | Approved | October 30, 1986 | Standard |
| Supplement | 6 | Labeling | Approved | June 26, 1985 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | January 24, 1985 | Standard |
| Supplement | 4 | Manufacturing (CMC) | Approved | February 28, 1984 | Standard |
| Original application | 1 | Type 5 - New Formulation or New Manufacturer | Approved | February 19, 1982 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20230823). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE 0.25% Acetic Acid Irrigation, USP, is indicated as a constant or intermittent bladder rinse to help prevent the growth and proliferation of susceptible urinary pathogens (especially ammonia forming bacteria) in the management of patients who require prolonged placement of an indwelling urethral catheter. It also may be used for periodic irrigation of an indwelling catheter to help maintain patency by reducing the formation of calcium encrustations.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION As required for urologic irrigation. 0.25% Acetic Acid Irrigation USP may be administered by gravity drip via an administration set connected to an indwelling urethral catheter designed for continuous or intermittent two-way flow. For continuous or intermittent irrigation, the rate of administration will correspond roughly to the rate of urine flow and should be adjusted to maintain a urinary effluent pH of 4.5 to 5.0. Nitrazine or other pH paper may be used to monitor pH, preferably at least four times daily. Drip rate should be adjusted as necessary to maintain desired pH; increasing flow rate reduces pH value and vice versa. With continuous or intermittent irrigation, each patient will require a volume of approximately 500 to 1500 mL per 24 hours. Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store. This drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS 0.25% Acetic Acid Irrigation USP is not for injection. This solution is contraindicated for irrigation during transurethral surgical procedures.
Warnings
openFDA Drug LabelingWARNINGS FOR UROLOGIC IRRIGATION ONLY. NOT FOR INJECTION. Use of this solution in patients with mucosal lesions of the urinary bladder may be harmful due to irritation of the lesion. Absorption via open lesions of the bladder mucosa may result in systemic acidosis. Do not warm above 150°F (66°C). After opening container, the contents should be used promptly in order to minimize the possibility of bacterial growth or pyrogen formation. Discard unused portion of irrigating solution since it contains no preservative.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Systemic acidosis, pain, and hematuria have been reported in patients receiving urinary bladder irrigation with 0.25% acetic acid solution. If an adverse reaction does occur, discontinue administration of the irrigant, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination, if deemed necessary.
Description
openFDA Drug LabelingDESCRIPTION Each 100 mL contains: Glacial Acetic Acid USP 0.25 g Water for Injection USP qs pH: 3.1 (2.8-3.4) Calculated Osmolarity: 42 mOsmol/liter The formula of the active ingredient is: Ingredient Molecular Formula Molecular Weight Glacial Acetic Acid USP CH 3 COOH 60.05 0.25% Acetic Acid Irrigation USP is a prediluted, sterile, nonpyrogenic aqueous solution suitable for urologic irrigation. It contains no preservatives or added buffers. The solution is hypotonic. The plastic container is a copolymer of ethylene and propylene formulated and developed for parenteral drugs. The copolymer contains no plasticizers and exhibits virtually no leachability. The plastic container is also virtually impermeable to vapor transmission and therefore, requires no overwrap to maintain the proper drug concentration. The safety of the plastic container has been confirmed by biological evaluation procedures. The material passes Class Vl testing as specified in the U.S. Pharmacopeia for Biological Tests — Plastic Containers. These tests have shown that the container is nontoxic and biologically inert. Not made with natural rubber latex, PVC or DEHP.
Overdosage
openFDA Drug LabelingOVERDOSAGE Systemic absorption is unlikely unless there are open lesions of the bladder mucosa that have gone undetected. In such event, discontinue the irrigation, evaluate the patient for possible systemic acidosis, intravascular hemolysis, and circulatory overload and institute appropriate countermeasures as indicated. See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED 0.25% Acetic Acid Irrigation USP is supplied sterile and nonpyrogenic in 1000 mL and 500 mL PICTM (Plastic Irrigation Containers) packaged 16 per case. NDC Cat. No. Size 0.25% Acetic Acid Irrigation USP 0264-2304-00 R6600-01 1000 mL 0264-2304-10 R6601-01 500 mL Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] However, brief exposure up to 40°C does not adversely affect the product. Do not warm above 150°F (66°C).
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ACETIC ACID. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | December 27, 2017 | B. Braun Medical Inc | Presence of Particulate Matter: identified as polyethylene, which is consistent with the material used to manufacture the contain cap | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0264-2304-00 | 0264-2304 | B. Braun Medical Inc. | 16 CONTAINER in 1 CASE (0264-2304-00) / 1000 mL in 1 CONTAINER | August 6, 1979 |
| 0264-2304-10 | 0264-2304 | B. Braun Medical Inc. | 16 CONTAINER in 1 CASE (0264-2304-10) / 500 mL in 1 CONTAINER | August 6, 1979 |
| 0338-0656-04 | 0338-0656 | Baxter Healthcare Corporation | 1000 mL in 1 BOTTLE, PLASTIC (0338-0656-04) | February 19, 1982 |
| 0264-2304 | 0264-2304 | B. Braun Medical Inc. | — | August 6, 1979 |
| 0338-0656 | 0338-0656 | Baxter Healthcare Corporation | — | February 19, 1982 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 12 sections on this page.